Encompass Health (NYSE:EHC) Price Target Raised to $118.00 at Barclays

Encompass Health (NYSE:EHC) had its price target boosted by Barclays from $116.00 to $118.00 in a research report sent to investors on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other analysts have also weighed in on the stock. KeyCorp raised their price target on shares of Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a report on Tuesday, October 29th. Royal Bank of Canada lifted their price target on shares of Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Truist Financial restated a “buy” rating and set a $116.00 price objective (up from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Finally, William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a research note on Friday. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Encompass Health presently has an average rating of “Buy” and a consensus target price of $107.33.

Encompass Health Price Performance

Shares of Encompass Health stock opened at $99.86 on Friday. The stock has a market capitalization of $10.06 billion, a price-to-earnings ratio of 24.12, a PEG ratio of 1.18 and a beta of 0.90. The firm has a fifty day simple moving average of $96.28 and a 200-day simple moving average of $95.19. Encompass Health has a 1-year low of $72.37 and a 1-year high of $104.55. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.88.

Encompass Health (NYSE:EHC) last issued its earnings results on Thursday, February 6th. The company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.05 by $0.12. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. On average, sell-side analysts expect that Encompass Health will post 4.29 earnings per share for the current year.

Hedge Funds Weigh In On Encompass Health

A number of large investors have recently modified their holdings of EHC. Sequoia Financial Advisors LLC lifted its stake in Encompass Health by 21.4% in the fourth quarter. Sequoia Financial Advisors LLC now owns 2,555 shares of the company’s stock worth $236,000 after purchasing an additional 451 shares during the last quarter. HighTower Advisors LLC increased its stake in shares of Encompass Health by 10.3% during the fourth quarter. HighTower Advisors LLC now owns 18,955 shares of the company’s stock valued at $1,751,000 after buying an additional 1,764 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Encompass Health by 10.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 744,046 shares of the company’s stock worth $68,713,000 after acquiring an additional 70,418 shares during the period. Taika Capital LP bought a new stake in Encompass Health in the fourth quarter valued at $351,000. Finally, AlphaQuest LLC increased its position in Encompass Health by 216.5% during the 4th quarter. AlphaQuest LLC now owns 28,700 shares of the company’s stock valued at $2,650,000 after purchasing an additional 19,633 shares during the period. 97.25% of the stock is currently owned by institutional investors.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.